Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 437 (TSX: $FAF.TO) (OTC: $EDXC) (CSE: $XCX.C) (TSX: $VIVO.TO)
Delta, Kelowna, BC, July 7, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Fire & Flower Holdings Corp. and its wholly-owned subsidiary Fire & Flower Inc. (TSX: FAF) (OTCQX: FFLWF), announced the openings of its first two cannabis retail stores adjacent to Circle K locations in the province of Alberta.
Through this initiative, Fire & Flower is expected to benefit from high traffic Circle K locations to deliver an unprecedented level of convenience to cannabis customers, maximizing the benefit of the Spark PerksTM program and Spark FastlaneTM online ordering services at conveniently located stores.
The two stores in Calgary and Grande Prairie are expected to be the first of additional opportunities to co-locate cannabis retail stores in the future. The co-located stores will be owned and operated by Fire & Flower and are separate from the adjacent Circle K in accordance with all applicable regulations. It is anticipated that the Grande Prairie store will open the week of July 6, 2020 and it is anticipated the Calgary store will open the week of July 13, 2020.
"As we continue to build our relationship with Alimentation Couche-Tard, Fire & Flower is very pleased to be embarking on this initiative together," shared Trevor Fencott, Chief Executive Officer of Fire & Flower. "We believe that combining convenient pickup locations with digital engagement offered by the Hifyre platform and Spark Perks program presents our customers with a differentiated value proposition in an increasingly competitive cannabis retail market. This approach to innovation in omni-channel and convenience-oriented cannabis retail differentiates Fire & Flower and positions us well to capitalize on both domestic and international opportunities."
Endexx® Corporation (OTC: EDXC) announced the e-commerce launch of RubyBees™ Hemp Infused Honey. RubyBees™ is now available in 950mg and 120mg jars for purchase on CBD Unlimited’s website.
Peter Boyer created RubyBees Hemp Honey when he was first introduced to CBD Unlimited’s hemp-derived CBD, an active ingredient derived directly from the hemp plant that exhibits soothing properties, as a way to ease the symptoms of his daughter. Longtime Endexx shareholder, Richard Steinhart, has long believed in the therapeutic benefits of CBD and suggested Boyer consult his daughter’s doctor about trying CBD sublingual oil alongside the medication she already takes for her cerebral palsy and epilepsy.
“As a father with a special needs daughter, I was searching for a way to help improve Ruby’s life. After working with CBD Unlimited and using their hemp-derived isolate, the positive change in Ruby’s everyday life was apparent. Utilizing honey as the delivery system and implementing the knowledge of proper dosages provided by the CBDU team, the tasty treat doubles as an effective way to enjoy the benefits of CBD. With their expansive knowledge and expertise in the industry, working with CBD Unlimited was a clear step in the right direction. We at RubyBees are eager and excited to be a part of such an incredible industry and to be working with a company focused on improving the lives of the people we care for,” commented Founder of RubyBees, Peter Boyer.
Great for coffee, tea, power drinks, toast spread, or for cooking, RubyBees Hemp Honey products are made with clover honey and infused with 10mg of hemp-derived isolate per serving while containing zero percent THC, no gluten, and no GMO’s. RubyBees Hemp Honey is also available in honey stick format, lab tested, and certified.
“We at CBD Unlimited are incredibly grateful and excited to offer our CBD in a product from a company as inspiring as RubyBees,” commented Todd Davis, CEO and Chairman of Endexx. “Whether the product is used as a therapeutic treatment or as a pick-me-up snack, we are confident that the RubyBees Hemp Honey will soon become a consumer favorite and continue to make waves in the CBD industry.”
AMP German Cannabis Group Inc. (CSE: XCX) announced further to its June 5, 2020 news release that The Office of Medical Cannabis ("OMC"), the government organization of the Netherlands for distribution of medical cannabis products, has notified AMP that it will resume exports of EU-GMP medical cannabis to Germany. The OMC will deliver 3,000 grams per month to each German importer due to the high demand and restricted supply currently available for Germany.
AMP has ordered Bedrocan International branded products to be exported by OMC on a monthly basis beginning July 2020. AMP has received all the required licenses to import irradiated cannabis flowers from the Dutch and German government authorities.
Dr. Stefan Feuerstein, Director and President of AMP, commented: "All pieces of the puzzle have come together with the start of our first import. We will be booking our first revenue from the sale of our Bedrocan products this month and hope to receive a higher amount from the Netherlands in August 2020. We are also on track to sign a definitive supply agreement with a Canadian supplier and will be adding pharmaceutical distribution partners that focus on medical cannabis exclusively to our distribution network covering Germany. Our next step is to increase import volumes from Canada in conjunction with developing AMP's medical cannabis brands for the German market."
VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF), a leading provider of premium cannabis products and services and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited, ABcann Medicinals Inc. and Harvest Medicine Inc., who provided an update on its global medical business, which operates in Canada, Germany and Australia.
"One of our top strategic priorities is to focus on the global medical cannabis market, directly servicing tens of thousands of patients and investing in product development initiatives that prioritize high-quality novel products," said Barry Fishman, CEO of VIVO. "We've recently made significant progress on a number of key initiatives, which will help solidify our market presence as a company that is committed to delivering solutions for patients and healthcare professionals on an international scale."
VIVO believes that significant growth in medical cannabis utilization will be driven by several factors including:
1. Accelerating legalization of medicinal cannabis globally
2. Mounting real-world and clinical evidence of therapeutic benefits
3. Increasing clinician adoption of medical cannabis as a viable therapeutic option
4. Growing reimbursement by governments and third-party payors
5. Improving patient and healthcare practitioner awareness, education and access
6. Introducing new medical-grade, precise-dosed, stable formulations
7. Removing the sales tax on medical cannabis in Canada
The Company is pleased to announce several initiatives that advance the Company's impact within the global medical cannabis market.
Shoppers Drug Mart Partnership
VIVO has entered into both a product supply agreement and a clinic services agreement with Medical Cannabis by Shoppers™. As previously announced, VIVO's two licensed producers will offer a broad portfolio of Canna Farms™ and Beacon Medical™ branded medical cannabis products through the Medical Cannabis by Shoppers™ online sales platform, including its latest Cannabis 2.0 offerings such as chocolates and extracts making these products accessible to Medical Cannabis by Shoppers™ patients across Canada.
Under the terms of the clinic services agreement, VIVO's subsidiary, Harvest Medicine, will provide cannabis education services to patients who are appropriate candidates for cannabinoid-based products available from Medical Cannabis by Shoppers™ and provide consulting services to its Cannabis Care team.
Launch of Beacon Medical Oils in Australia
VIVO's subsidiary, Beacon Medical Australia, has entered into a supply agreement with MediPharm Labs Australia to purchase pharmaceutical quality (GMP certified) cannabis oils for the Australian market.
As previously announced, under the agreement MediPharm Labs Australia will supply its full range of GMP-certified, formulated CBD and THC cannabis oils to Beacon Medical Australia for further distribution under the Beacon Medical branding. The addition of cannabis oils to Beacon's Australian portfolio is an important step towards capturing market share in Australia's growing medical cannabis market.
Veterans House Partnership
VIVO has entered into a collaboration agreement with Veterans House ("Veterans House"), under which the Company will provide sponsorship and support to joint programs for Canadian Armed Forces veterans. Veterans House is a federally registered non-profit organization that provides veterans suffering from mental illness and operational stress injuries such as post-traumatic stress disorder, with access to counseling and peer support programs.
"Canna Farms is a long-standing supporter of veterans, providing access to leading medical cannabis products and programs," said Fabian Henry, Senior Director of Operations at Veterans House. "The team at VIVO has shown an ongoing commitment to Canadian veterans and we look forward to working more closely together to serve this community."
"We are proud to be associated with Veterans House," said Mr. Fishman. "Our veterans have dedicated their lives to defending the rights and freedoms we have in Canada. We are honoured to play an important role in enhancing the quality of life for our veterans."
Medical Product Line Expansion
VIVO also introduced softgel capsules, with several cannabinoid concentrations
available, through its Canna Farms on-line medical marketplace in the coming weeks. Softgel capsules provide patients with a convenient format to ingest cannabis in a precisely dosed format.
The introduction of softgels follows the successful launch of VIVO's Cannabis 2.0 product offerings (including chocolates and extracts) into the Canadian medical market, increasing choice for the Company's more than 20,000 registered patients.
The Canna Farms store now carries six leading medical brands including GTEC, Aqualitis and Pure Sunfarms. "Our web-based medical store continues to be a key point of connection for Canadian patients to conveniently access medical cannabis products," said Daniel Laflamme, President of Canna Farms. "Having a consistent supply of medical products has been an industry-wide concern and we continue to enhance our manufacturing processes and relationships with other established high-quality LP partners, to supply our medical patients with a wide range of product options."
Product Development Progress
VIVO moved into the next stage of product innovation with partner Pharmascience Inc., a global pharmaceutical company based in Montreal, for the development of a line of specific medical cannabis formulations produced under pharmaceutical quality standards intended to maximize the benefit to patients.
"Healthcare professionals and patients are increasingly searching for precisely-controlled, high-quality, standardized dosage forms of medical cannabis. VIVO has invested in several product development projects with proven partners experienced in formulating complex medical products," stated Mr. Fishman.
EU-GMP Follow-up Audit Completed
A follow-up EU-GMP audit was recently completed at VIVO's ABcann Medicinal facility in Napanee. This is an important step towards EU GMP-certification and is a requirement to export medical cannabis products from Canada for sale in Germany and other European countries.
Real-World Evidence Collaboration
The Company entered into a partnership with privately held Reformulary Group, an innovative healthcare company dedicated to helping Canadians make sense of medicine (prescription drugs and medical cannabis). VIVO has agreed to provide clinical support, through the Company's Harvest Medicine clinics, to patients who access Reformulary Group's Cannabis Standard™ platform. Cannabis Standard is an ecosystem of expert recommendations, patient-powered tools, and independent information to help Canadians and healthcare professionals make smarter, more informed decisions about choosing medical cannabis.
"Cannabis Standard™ applies the same formula that we've used so successfully on the prescription medication side. We gathered a panel of independent medical experts, conducted a comprehensive review all of the available evidence globally, and created user-friendly tools to help Canadians navigate the medical cannabis space," said Helen Stevenson, Reformulary Group founder and CEO. "At its core, Cannabis Standard™ is about helping patients benefit from and contribute to the growing base of medical cannabis research, and we look forward to working closely with the team at VIVO to advance patient outcomes."
VIVO has also engaged Strainprint Technologies™, a leader in cannabis data and analytics, to examine real-world evidence of its products, linking utilization and efficacy for several of the leading indications treated with medical cannabis from thousands of patients. This evidence is being used by healthcare professionals to assist in determining optimal treatment options and by patients to help navigate their medical cannabis journey. VIVO is the first Canadian LP to provide this valuable information on its products to key stakeholders.
Patient Support Under COVID-19
Health Canada recently announced that due to COVID-19, it is temporarily extending the expiry date of registrations by six months for patients who are having difficulty accessing their health care prescriber to obtain a new medical document.
Since Harvest Medicine temporarily moved its entire clinic operations to telemedicine in late Q1 2020, the feedback from patients and prescribing clinicians adapting to virtual visits has been overwhelmingly positive.
"Not only has there been no lapse in ongoing care for our patients during COVID-19, but our dedicated team was able to scale up to meet increased patient demand for visits on our HMED Connect mobile application platform which have more than tripled during the pandemic," stated Carole Chan, President of Harvest Medicine. "We understand the importance of in-person consultations for certain patient populations, and we will continue to offer this option when clinics re-open in the near future with enhanced protocols to keep patients and staff safe."
VIVO is confident that it will benefit from Health Canada's recent announcement and Harvest Medicine's ability to continue to provide high-quality patient services during COVID-19.
Product Identification Enhancement
VIVO, through its global Beacon Medical™ brand has simplified its consumer-facing product naming conventions and added Product Identification Numbers (PINs) to its core Canadian offering to better support doctors, pharmacists and patients in navigating medical cannabis. "Introducing PINs will enable Canadian insurers to more easily navigate our products," commented Matt Patterson, Vice President of Medical Strategy.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Contact Investorideas.com
800 665 0411
